Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial.

ABSTRACT:

SUBMITTER: Mina R 

PROVIDER: S-EPMC8651653 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature